Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Chlamydia pneumoniae infections].

Naoyuki Miyashita1

  • 1Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki-shi, Okayama 701-0192 Japan. nao@med.kawasaki-m.ac.jp

Kekkaku : [Tuberculosis]
|October 14, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to: Do current data justify the framing of respiratory fluoroquinolones and lascufloxacin in the 2024 JRS adult pneumonia guideline digest?

Respiratory investigation·2026
Same author

Risk factors for community-acquired pneumonia in older adults in Japan after the introduction of the childhood PCV13.

BMC infectious diseases·2026
Same author

Impact of the "DPC Special Provision" on COVID-19 inpatient case identification in Japanese administrative databases.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy·2026
Same author

Efficacy of garenoxacin in patients with macrolide-resistant <i>Mycoplasma pneumoniae</i> pneumonia.

Antimicrobial agents and chemotherapy·2026
Same author

Clinical features of macrolide-resistant Mycoplasma pneumoniae pneumonia: Can the JRS pneumonia guidelines be applied?

Respiratory investigation·2026
Same author

Verification of the JRS adult pneumonia clinical practice guidelines 2024: Sensitivity and specificity of the mycoplasma pneumonia diagnostic prediction score.

Respiratory investigation·2026

Chlamydia pneumoniae causes respiratory illnesses and may persist long-term. This persistence is linked to chronic diseases like asthma and COPD, potentially due to aberrant forms of the bacteria.

Area of Science:

  • Microbiology
  • Immunology
  • Pathogenesis

Context:

  • Chlamydia pneumoniae is an intracellular bacterium responsible for human respiratory tract infections.
  • Infections range from mild/asymptomatic to severe pneumonia, bronchitis, pharyngitis, and sinusitis.
  • High seroprevalence suggests widespread exposure, with potential links to asthma and COPD exacerbations.

Purpose:

  • To explore the mechanisms and implications of persistent Chlamydia pneumoniae infections.
  • To understand the role of aberrant forms (AF) in bacterial persistence.
  • To investigate the connection between persistent infections and chronic disease development.

Summary:

  • Chlamydia pneumoniae can establish prolonged infections, persisting for months or years.

Related Experiment Videos

  • Under stress, C. pneumoniae can enter an aberrant form (AF) within host cells, enabling long-term survival.
  • These persistent infections may trigger chronic inflammatory responses contributing to diseases like atherosclerosis, asthma, and COPD.

    • Impact:

    • Understanding chlamydial persistence is crucial for managing chronic inflammatory and infectious diseases.
    • Identifying mechanisms of persistence may lead to novel therapeutic strategies targeting chronic C. pneumoniae infections.
    • This research highlights the significant public health impact of a common respiratory pathogen.